| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 74 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 27.10. | ECARX Powers Global Launch of the smart #5 Premium Mid-Size SUV | 557 | GlobeNewswire (Europe) | SHANGHAI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) ("ECARX" or the "Company"), a global mobility technology company, in partnership with AMD, the high performance and adaptive... ► Artikel lesen | |
| 27.10. | Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 | 108 | GlobeNewswire (Europe) | Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN... ► Artikel lesen | |
| 27.10. | Gapwaves AB: Gapwaves and Valeo enter into a joint development and supply agreement for radar antennas | 280 | GlobeNewswire (Europe) | Gothenburg, October 27, 2024: Gapwaves, a world leader in innovative waveguide technology, and Valeo, a French world leader in ADAS systems, have entered into an agreement regarding the development... ► Artikel lesen | |
| 27.10. | Biogen Inc.: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 | 522 | GlobeNewswire (Europe) | The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamabFelzartamab, an investigational... ► Artikel lesen | |
| 27.10. | Novartis Pharma AG: Novartis oral Fabhalta (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial | 797 | GlobeNewswire (Europe) | New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope - a key measure of... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| SUPER MICRO COMPUTER | 2.920 |
| EVOTEC | 2.175 |
| TUI | 1.858 |
| BAYER | 1.795 |
| NVIDIA | 1.681 |
| NEL | 1.284 |
| RENK GROUP | 1.147 |
| RHEINMETALL | 1.046 |
| TESLA | 883 |
| PALANTIR TECHNOLOGIES | 833 |
| DEUTSCHE BANK | 781 |
| VOLKSWAGEN | 757 |
| MICROSTRATEGY | 719 |
| BYD | 699 |
| PLUG POWER | 666 |
| COMMERZBANK | 660 |
| BASF | 637 |
| JINKOSOLAR | 618 |
| MERCEDES-BENZ | 595 |
| AMAZON | 579 |
| DEUTSCHE TELEKOM | 555 |
| INTEL | 554 |
| BMW | 548 |
| ALLIANZ | 541 |
| THYSSENKRUPP | 537 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
